US Patent

US7544373 — Minocycline oral dosage forms for the treatment of acne

Formulation · Assigned to Medicis Pharmaceutical Corp · Expires 2027-04-02 · 1y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects controlled release oral dosage forms of minocycline hydrochloride for the treatment of acne.

USPTO Abstract

Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.

Drugs covered by this patent

minocycline-hydrochloride (MINOCYCLINE HYDROCHLORIDE)

Patent Metadata

Patent number: US7544373
Jurisdiction: US
Classification: Formulation
Expires: 2027-04-02
Drug substance claim: No
Drug product claim: Yes
Assignee: Medicis Pharmaceutical Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.